US obesity rates: astronomical but leveling
February 1st 2012The latest National Health and Nutrition Examination Survey (NHANES) data from 2009-2010 reveal that more than 1 in 3 adult men and women in the United States are obese, as are more than 1 in 6 children and adolescents. The good news I that the figures for both adults and children are largely unchanged from previous periods, suggesting a slowing or leveling off of obesity prevalence.
Examining the evidence on vitamin D, calcium, and CVD risk
February 1st 2012The pivotal roles of vitamin D and calcium in skeletan metabolism are well known. It's their potential non-skeletal health effects-particularly in preventing cardiovascular disease (CVD)-that are controversial. In vitro and in vivo experimental studies have shown that vitamin D (Figure 1) and calcium (Figure 2) act independently and together to influence multiple physiologic processes that may modify CVD risk.
Oral Contraceptives: What you need to know about the latest formulations
February 1st 2012An estimated 12 million woemn in the United States use the oral contraceptive (OC) pill, making it the most popular reversible method of birth control. Many new hormonal delivery systems offer benefit superior to those of the pill. The vaginal ring, injection, and patch allow less-frequent dosing, which may improve compliance. The intrauterine device and implant are significantly more effective than the pill, with failure rates rivaling those of sterilization. Nevertheless, the pill remains the method of choice for the majority of women, and pharmaceutical companies are therefore eager to develop new formulations. Since the pill was first introduced more than 50 years ago, many of these new formulations have been little more than updated packaging. However, several new brands have emerged recently that are advertised as having noncontraceptive benefits beyond those of older pill formulations, as well as improved bleeding and side-effect profiles.
Infection resistance dips during ovulation
February 1st 2012High levels of estradiol (E2), present during ovulation and immediately after, diminish a woman's ability to protect against infection, according to a recent study from Spain and Austria. This means that women are more susceptible to fungal infection, such as with Candida Albicans (C albicans), or sexually transmitted diseases, such as HPV or HIV, during ovulation than at any other time during the reproductive cycle.
Defer BMD testing intervals for older women, study suggests
January 26th 2012Baseline T score is the most useful way to determine how often to test bone mineral density (BMD) in older postmenopausal women with normal BMD or osteopenia at initial assessment, according to a study published in the New England Journal of Medicine (2012;366[3]:225-233).
The Link Between Parabens and Breast Cancer: How Much Worry Is Warranted?
January 20th 2012Over the past few years, there has been great concern over the presence of alkyl esters of p-hydroxybenzoic acid (parabens) in consumer products and their link to breast cancer. These compounds have been found in human blood, milk, urine, and breast tissue.
Laparoscopic Surgery & Malpractice Risk, Part 2: Laparoscopic Hysterectomy
January 19th 2012Kevin Giordano, Esq. and John O’Grady, MD, examine two laparoscopic hysterectomies that resulted in occult ureteric injury.Is it possible that the same event might be considered the standard of practice in one case but not the other?
Laparoscopic Surgery & Malpractice Risk, Part 1: Diagnostic Laparoscopy
January 12th 2012Is the concept of an “accepted complication”-or the identified limitations of medical science-a shield to malpractice claims? Kevin Giordano, Esq. and John O’Grady, MD, explore liability risks of diagnostic laparoscopy.
Educational Tutorial: GDM & DM in Pregnancy
January 9th 2012Gestational diabetes is a serious concern in pregnancy for both the fetus and mother. In this educational tutorial, review the epidemiology, classification, pathogenesis of glucose intolerance, consequences for mother and fetus, fetal evaluation, screening and more.
Addition of Bevacizumab to Ovarian Cancer Treatment is Associated With Better Survival
January 8th 2012Two new studies published in the New England Journal of Medicine point to the importance of using bevacizumab in the treatment of ovarian cancer. Bevacizumab, a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor, has shown single-agent activity in women with recurrent tumors.